Aktienanalyse zu Lisata Therapeutics Inc (LSTA)LSTALisata Therapeutics Inc

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lisata Therapeutics Inc (LSTA) is currently not a strong buy due to significant operational challenges and recent downgrades by analysts. The stock is trading at $1.69, which is down 23.53% over the past year. The RSI is at 64.95, indicating it is nearing overbought territory, while the forward P/E ratio is a low 2.71, suggesting potential undervaluation. However, the company has cut 72% of its workforce, which raises concerns about its operational capacity and future growth prospects.